EV

Evolent Health, Inc.

EVHHealthcareNASDAQ

Health Information Services · Last scanned Oct 26, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$1.88B
-26.6% YoY
Net Income
-$534.5M
-767.4% YoY
EBITDA
-$361.3M
-551.3% YoY
Free Cash Flow
$126.9M

Scan Results

Daily timeframe
5 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Oct 20▼ RSI OverboughtRSI 70.3, above 70, stock may be overbought
Oct 15CONFIRMED▼ RSI OverboughtRSI 79.0, above 70, stock may be overbought
About Evolent Health, Inc.

Part of the healthcare sector, Evolent Health, Inc. (EVH) is listed under Health Information Services. The company carries a $542.7M market cap, placing it firmly in the small-cap category. The company offers integrated value-based care platform for health plan administration and management.

Where EVH stands vs its 150-day and 200-day moving averages

As of the October 20, 2026 close, EVH finished 11.44% above its 150-day moving average ($4.02) and 16.36% above its 200-day moving average ($3.85). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is EVH overbought or oversold?

At the October 20, 2026 close, EVH's RSI(14) was 70.3, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$542.7M
Fwd P/E11.89
EPS$-4.49
Beta1.02
52W Change-37.2%
Dividend Yield0.00%
ROE-67.0%
Analysis

On the balance sheet, EVH has $115.7M in cash with $970.4M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $126.9M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -67.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $1.35B (2022) to $1.88B (2025), reflecting a 39% increase over the period.

Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing EVH.

Links
More Healthcare stocks
Browse all stocks →
⚠Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms